1.

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy

2.

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy

3.

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy

4.

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy

5.

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy

1.

Broadening the Knowledge Base in Policymaking: Notes on a Symposium on Technology Assessment in the Walloon Parliament

2.

Broadening the Knowledge Base in Policymaking: Notes on a Symposium on Technology Assessment in the Walloon Parliament

3.

Broadening the Knowledge Base in Policymaking: Notes on a Symposium on Technology Assessment in the Walloon Parliament

1.

Governance in Japan and Belgium: Building on Experiments with Technology Assessment and TA-like Activities

2.

Governance in Japan and Belgium: Building on Experiments with Technology Assessment and TA-like Activities

3.

Governance in Japan and Belgium: Building on Experiments with Technology Assessment and TA-like Activities

1.

Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England

2.

Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England

3.

Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England

4.

Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England

5.

Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England

1.

Implementing the EU HTA regulation: Insights from semi-structured interviews on patient expectations, Belgian and European institutional perspectives, and industry outlooks

1.

The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa

2.

The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa

3.

The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa

1.

Understanding the adoption and use of point-of-care tests in Dutch general practices using multi-criteria decision analysis

1.

Using real-world data (RWD) in health technology assessment (HTA) practice: A comparative study of 5 HTA agencies

1.

Conditional financing in health technology assessment practice: The Dutch experience

2.

Conditional financing in health technology assessment practice: The Dutch experience

3.

Conditional financing in health technology assessment practice: The Dutch experience